XNASELUT
Market cap55mUSD
Jan 08, Last price
3.40USD
1D
0.00%
1Q
-9.33%
IPO
138.85%
Name
Aziyo Biologics Inc
Chart & Performance
Profile
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 24,745 3.76% | 23,849 -49.68% | ||||
Cost of revenue | 45,282 | 53,838 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (20,537) | (29,989) | ||||
NOPBT Margin | ||||||
Operating Taxes | 28 | 34 | ||||
Tax Rate | ||||||
NOPAT | (20,565) | (30,023) | ||||
Net income | (37,656) 14.47% | (32,897) 32.48% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 10,085 | 10,484 | ||||
BB yield | ||||||
Debt | ||||||
Debt current | 3,871 | 9,222 | ||||
Long-term debt | 25,991 | 30,408 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 13,275 | 1,083 | ||||
Net debt | 10,586 | 22,641 | ||||
Cash flow | ||||||
Cash from operating activities | (21,761) | (21,902) | ||||
CAPEX | (346) | (540) | ||||
Cash from investing activities | 14,208 | (540) | ||||
Cash from financing activities | 9,840 | 9,003 | ||||
FCF | (12,549) | (20,667) | ||||
Balance | ||||||
Cash | 19,276 | 16,989 | ||||
Long term investments | ||||||
Excess cash | 18,039 | 15,797 | ||||
Stockholders' equity | (175,621) | (137,972) | ||||
Invested Capital | 180,158 | 173,420 | ||||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 18,161 | 13,833 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (16,789) | (26,423) | ||||
EV/EBITDA | ||||||
Interest | 5,796 | 5,118 | ||||
Interest/NOPBT |